Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
P3 Health Partners Inc. incurred loan of up to $25.0 million with VBC Growth SPV 2, LLC at 17.5% per annum maturing September 30, 2027.
- Instrument
- loan
- Principal
- up to $25.0 million
- Counterparty
- VBC Growth SPV 2, LLC
- Rate
- 17.5% per annum
- Maturity
- September 30, 2027
- Event
- incurrence
Exact text from the filing
of independent, disinterested directors of the Company. Promissory Note The Promissory Note was issued by P3 LLC to VBC 2 on March 22, 2024, and provides for funding of up to $25.0 million, available for draw by P3 LLC in two tranches, as follows: (i) a first tranche of $10.0 million available to P3 LLC upon the Effective Date, and (ii) a second tranche of $15.0
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
P3 Health Partners Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $346.9 million, net income Net loss was $69.1 million. Guidance reaffirmed.
- Period
- fourth quarter and full year ended December 31, 2023
- Revenue
- $346.9 million
- Net income
- Net loss was $69.1 million
- Guidance
- reaffirmed
- Result
- reported results
Exact text from the filing
for the P3 model is as high as ever and that our demonstrated ability to bend the cost curve is driving this demand.” Fourth Quarter 2023 Financial Results • Total revenue was $346.9 million, an increase of 34% compared to $258.2 million in the fourth quarter of the prior year • Capitated revenue was $342.8 million, an increase of 35% compared to $254.0 million in
View on SEC.gov